Menu Close

Gabapentin 300mg ScieGen Pharmaceuticals SG 180 Pill – yellow capsule/oblong

Pill with imprint SG 180 is Yellow, Capsule/Oblong and has been identified as Gabapentin 300 mg. It is supplied by ScieGen Pharmaceuticals, Inc.

Gabapentin is used in the treatment of Back Pain; Postherpetic Neuralgia; Epilepsy; Chronic Pain; Seizures and belongs to the drug class gamma-aminobutyric acid analogs. Risk cannot be ruled out during pregnancy. Gabapentin 300 mg is not a controlled substance under the Controlled Substances Act (CSA).

Gabapentin 300 mgSG180 ScieGen Pharmaceuticals
Gabapentin 300 mgSG180 ScieGen Pharmaceuticals

Gabapentin

Imprint
SG 180
Strength
300 mg
Color
Yellow
Size
19.00 mm
Shape
Capsule/Oblong
Availability
Prescription only
Drug Class
Gamma-aminobutyric acid analogs
Pregnancy Category
C – Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
ScieGen Pharmaceuticals, Inc.
National Drug Code (NDC)
50228-0180
Inactive Ingredients
corn starch, magnesium silicate, gelatin, titanium dioxide, FD&C Red No. 40, D&C Yellow No. 10, sodium lauryl sulfate

Note: Inactive ingredients may vary.

Gabapentin is a medication used to treat seizures (epilepsy) and nerve pain (neuropathic pain). It belongs to a class of medications called anticonvulsants or antiepileptic drugs. Here’s a rundown of precautions, side effects, and how to take gabapentin:

Precautions:

  1. Allergies: Inform your doctor if you have any allergies to gabapentin or any other medications.
  2. Medical History: Disclose your medical history to your doctor, especially if you have a history of kidney disease, mood disorders (such as depression or bipolar disorder), substance abuse, or breathing problems.
  3. Pregnancy and Breastfeeding: Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding, as gabapentin may pose risks to the fetus or infant.
  4. Driving and Operating Machinery: Gabapentin may cause dizziness, drowsiness, or blurred vision, which can impair your ability to drive or operate machinery. Use caution when engaging in activities that require mental alertness until you know how gabapentin affects you.
  5. Alcohol and Sedatives: Avoid consuming alcohol or taking sedative medications while using gabapentin, as it can increase the risk of drowsiness and dizziness.
  6. Withdrawal: Do not stop taking gabapentin suddenly without consulting your doctor, as this can lead to withdrawal symptoms such as seizures, anxiety, insomnia, nausea, or sweating.

Side Effects:

Common side effects of gabapentin may include:

  • Dizziness
  • Drowsiness
  • Fatigue
  • Headache
  • Nausea
  • Blurred vision
  • Dry mouth
  • Weight gain
  • Tremors
  • Difficulty speaking
  • Memory problems

Less common but more serious side effects may include:

  • Suicidal thoughts or behavior
  • Mood changes (such as depression or anxiety)
  • Swelling of the hands, feet, or ankles
  • Rapid weight gain
  • Signs of infection (such as fever or sore throat)
  • Unusual bruising or bleeding
  • Severe skin reactions (such as rash, blistering, or peeling)

If you experience any severe or persistent side effects while taking gabapentin, contact your doctor immediately.

How to Take Gabapentin:

  1. Dosage: Take gabapentin exactly as prescribed by your doctor. Do not adjust your dosage without consulting your doctor first.
  2. Administration: Gabapentin is usually taken orally with or without food. Swallow the capsule or tablet whole with a full glass of water.
  3. Timing: Take gabapentin at the same times each day to maintain a consistent level of the medication in your body.
  4. Gradual Dosing: If you are starting gabapentin treatment or increasing the dosage, your doctor may recommend starting with a low dose and gradually increasing it over time to minimize side effects.
  5. Duration of Treatment: Continue taking gabapentin for the full duration of treatment prescribed by your doctor, even if you start to feel better.
  6. Storage: Store gabapentin at room temperature away from moisture and heat. Keep it out of reach of children and pets.

ScieGen Pharmaceuticals, Inc.

ScieGen Pharmaceuticals, Inc. is a key player in the generic pharmaceutical industry, known for its commitment to quality, innovation, and affordability. With a strong focus on research and development, regulatory compliance, and strategic growth, ScieGen continues to expand its presence in the U.S. and international markets. The company’s dedication to sustainable practices and corporate responsibility further underscores its role as a responsible and forward-thinking pharmaceutical provider.

ScieGen Pharmaceuticals, Inc. is a pharmaceutical company that specializes in the development, manufacturing, and marketing of generic prescription medications. Here’s an overview of ScieGen Pharmaceuticals, Inc.:

Company Overview

  1. Establishment and Headquarters:
    • Founded: ScieGen Pharmaceuticals was established to provide high-quality generic pharmaceuticals.
    • Headquarters: Hauppauge, New York, USA.
  2. Operations and Facilities:
    • Manufacturing: ScieGen operates manufacturing facilities that comply with stringent regulatory standards. The company’s facilities are designed to support the production of a wide range of dosage forms, including tablets, capsules, and powders.
    • Research and Development: The company focuses on R&D to develop new generic formulations and improve existing ones, ensuring they meet the highest quality standards.

Product Portfolio

  1. Generics:
    • Therapeutic Areas: ScieGen offers a broad range of generic medications across various therapeutic categories, including cardiovascular, central nervous system, gastrointestinal, anti-infective, and pain management drugs.
    • Dosage Forms: The company manufactures various dosage forms, such as tablets, capsules, and oral solutions.

Key Areas of Operation

  1. Regulatory Compliance:
    • Quality Assurance: ScieGen adheres to rigorous quality control measures and regulatory requirements set by the U.S. Food and Drug Administration (FDA) and other global regulatory bodies.
    • GMP Compliance: The company ensures that its manufacturing processes comply with Good Manufacturing Practices (GMP) to guarantee the safety, efficacy, and quality of its products.
  2. Research and Development:
    • Innovation: ScieGen invests in R&D to develop cost-effective generic alternatives to brand-name drugs, focusing on complex generics and niche therapeutic areas.
    • Pipeline: The company has a robust pipeline of products in various stages of development, aimed at expanding its market presence and addressing unmet medical needs.
  3. Manufacturing Excellence:
    • Advanced Technology: ScieGen’s manufacturing facilities are equipped with advanced technology to produce high-quality pharmaceuticals efficiently.
    • Capacity: The company’s facilities have significant production capacities to meet both domestic and international demand.

Strategic Growth

  1. Market Strategy:
    • Product Launches: ScieGen focuses on the timely launch of generic medications to capture market share and provide affordable options to patients.
    • Competitive Pricing: The company’s competitive pricing strategy ensures that its products are accessible to a broad patient population.
  2. Partnerships and Collaborations:
    • Expansion: ScieGen pursues strategic partnerships and collaborations to enhance its product offerings and expand its market reach.
    • Distribution Networks: The company has established robust distribution networks to ensure the widespread availability of its products.

Corporate Responsibility

  1. Sustainability:
    • Environmental Practices: ScieGen is committed to sustainable manufacturing practices, focusing on minimizing its environmental impact through efficient resource use and waste management.
  2. Community Engagement:
    • CSR Activities: The company engages in corporate social responsibility (CSR) initiatives aimed at improving healthcare access, supporting education, and contributing to community development.

Leave a Reply

Your email address will not be published. Required fields are marked *